Femasys Inc. reported a significant increase in sales for the first half of 2025, with sales rising by $257,908, or 52.4%, to $750,532 compared to $492,624 in the same period of 2024. This growth was attributed to the sales of FemaSeed and FemVue. However, the company experienced a net loss of $10.5 million for the six-month period ended June 30, 2025, compared to a net loss of $8.3 million for the same period in 2024. For the three-month period ended June 30, 2025, Femasys Inc. saw a sales increase of $187,784, or 84.8%, reaching $409,268 compared to $221,484 in the same quarter of 2024. The net loss for this quarter was reported at $4.6 million, compared to $4.7 million for the same period in 2024. Research and development expenses for the six months of 2025 increased by 17.0% to $4.4 million, primarily due to higher compensation and regulatory costs, while the three-month period saw a decrease in these expenses by 28.4% due to the commercialization of development products into inventory and reduced clinical costs. As of June 30, 2025, Femasys Inc. held approximately $3.2 million in cash and cash equivalents and had an accumulated deficit of approximately $137.7 million. The company anticipates that its current cash and cash equivalents will be sufficient to fund operations into early fourth quarter of 2025.